![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Found 31 studies with search of: | "Angiopeptin" |
Hide studies that are not seeking new volunteers.
|
|
1 | Recruiting | GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma | ||||
Condition: | Advanced Hepatocellular Carcinoma | |||||
Interventions: | Drug: Octreotide-LAR, Lanreotide Autogel; Drug: Octreotide-LAR or Lanreotide Autogel; Other: Locoregional treatments | |||||
2 | Active, not recruiting | Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel | ||||
Condition: | Acromegaly | |||||
Interventions: | Drug: Somatuline Autogel (lanreotide acetate); Behavioral: Home administration | |||||
3 | Completed | Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide-Autogel 120 mg | |||||
4 | Not yet recruiting | Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer | ||||
Condition: | Lymphocele | |||||
Interventions: | Drug: Lanreotide LP 90; Drug: Placebo lanreotide | |||||
5 | Recruiting | Treatment of the Dumping Syndrome With Lanreotide Autogel® | ||||
Condition: | Dumping Syndrome | |||||
Intervention: | Drug: Somatuline (Lanreotide Autogel®) | |||||
6 | Withdrawn | Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: lanreotide (Autogel formulation) | |||||
7 | Active, not recruiting | Lanreotide as Treatment of Polycystic Livers | ||||
Conditions: | Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney, Autosomal Dominant | |||||
Interventions: | Drug: Placebo; Drug: Lanreotide | |||||
8 | Completed | Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide Autogel and Octreotide LAR | |||||
9 | Completed | Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly | ||||
Condition: | Acromegaly | |||||
Interventions: | Drug: Octreotide-LAR or lanreotide; Procedure: Transsphenoidal adenomectomy | |||||
10 | Terminated | Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment | ||||
Condition: | Thyroid-Associated Ophthalmopathy | |||||
Intervention: | Drug: Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days | |||||
11 | Active, not recruiting | Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients | ||||
Condition: | Acromegaly | |||||
Interventions: | Drug: lanreotide (Autogel formulation); Drug: Pegvisomant | |||||
12 | Completed | Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide (Autogel formulation) | |||||
13 | Completed | Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | |||||
14 | Recruiting | Somatuline Autogel Preference and Health Economy Study | ||||
Condition: | Neuroendocrine Tumour With Carcinoid Symptoms | |||||
Intervention: | Drug: Lanreotide Autogel | |||||
15 | Recruiting | Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma | ||||
Condition: | Acromegaly Associated With Pituitary Gland Macroadenoma | |||||
Intervention: | Drug: Lanreotide autogel | |||||
16 | Completed | Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide (Autogel formulation) | |||||
17 | Completed | Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae | ||||
Condition: | Digestive Fistulae | |||||
Interventions: | Drug: Lanreotide microparticles; Drug: Placebo | |||||
18 | Recruiting | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | ||||
Conditions: | Intestinal Obstruction; Carcinoma; Peritoneal Neoplasms | |||||
Interventions: | Drug: Lanreotide (microparticle formulation); Other: Placebo | |||||
19 | Completed | Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide (Autogel formulation) | |||||
20 | Recruiting | Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours | ||||
Condition: | Endocrine Tumors | |||||
Interventions: | Drug: lanreotide (Autogel formulation); Other: Placebo | |||||
21 | Recruiting | Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours | ||||
Condition: | Neuroendocrine Tumours | |||||
Intervention: | Drug: lanreotide (Autogel formulation) | |||||
22 | Not yet recruiting | Open Label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on Long Term Treatment With Octreotide LAR 10 or 20 mg | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide Autogel 120 mg | |||||
23 | Terminated | Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome | ||||
Condition: | Malignant Carcinoid Syndrome | |||||
Interventions: | Drug: lanreotide Autogel (somatostatin analogue); Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue) | |||||
24 | Completed | Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: lanreotide (Autogel formulation), duration of treatment 46-48 weeks | |||||
25 | Recruiting | Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study | ||||
Condition: | Acromegaly | |||||
Intervention: | ||||||
26 | Completed | Somatuline Autogel: Acromegaly Self/Partner Injection Study | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Lanreotide (Autogel formulation) | |||||
27 | Not yet recruiting | Use of Somatostatin Analogue Therapy as Primary Medical Treatment of Acromegaly | ||||
Condition: | Acromegaly | |||||
Intervention: | Drug: Somatuline Autogel | |||||
28 | Completed | A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide | ||||
Condition: | Acromegaly | |||||
Intervention: | ||||||
29 | Not yet recruiting | Non Interventional Post Marketing Programme in Acromegaly | ||||
Condition: | Acromegaly | |||||
Intervention: | ||||||
30 | Not yet recruiting | Non Interventional Post Marketing Programme in Neuroendocrine Tumours | ||||
Condition: | Neuroendocrine Tumors | |||||
Intervention: | ||||||
31 | Completed | Cardiovascular Outcome After Surgery or Somatostatin Analogues | ||||
Condition: | Acromegaly | |||||
Intervention: | ||||||
![]() |